Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

anti-STn antibody-drug conjugate SGN-STNV

An antibody-drug conjugate (ADC) composed of an antibody directed against the tumor-associated carbohydrate antigen Sialyl Thomsen-nouveau (STn) conjugated to the cytotoxic agent monomethyl auristatin E (MMAE) via the MC-vc-PAB linker, with potential antineoplastic activity. Upon administration of the anti-STn ADC SGN-STNV, the anti-STn antibody targets and binds to STn expressed on tumor cells. Following internalization of SGN-STNV and release of MMAE, MMAE targets and binds to tubulin, and inhibits microtubule polymerization. This results in G2/M phase cell cycle arrest and apoptosis in STn-expressing tumor cells. STn, a tumor-associated carbohydrate antigen that is present on various tumor-associated glycoproteins including CA-125 and mucin-1 (MUC1), is expressed in multiple tumor types.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:ADC SGN-STNV
anti-Sialyl Thomsen-nouveau antibody-drug conjugate SGN-STNV
anti-STn ADC SGN-STNV
anti-STn vedotin ADC SGN-STNV
Code name:SGN STNV
SGN-STNV
SGNSTNV
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search